Intravenous palonosetron was effective in preventing chemotherapy-induced nausea and vomiting or managing delayed symptoms in most of the 40 non-Hodgkin lymphoma patients included in a study. The research published in the journal Supportive Care in Cancer found more than 85% of patients overall achieved a complete response.
Study: IV palonosetron can prevent, manage chemo-related symptoms
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.